

Title (en)

DEXTROSE AND INSULIN FLUID FORMULATION FOR INTRAVENOUS INFUSION

Title (de)

DEXTROSE UND INSULIN ENTHALTENDE FLUSSIGE ZUSAMMENSETZUNG ZUR INTRAVENÖSEN INFUSION

Title (fr)

PREPARATION DE FLUIDES A BASE DE DEXTROSE ET D'INSULINE DESTINEE A UNE INFUSION INTRAVEINEUSE

Publication

**EP 1231907 A2 20020821 (EN)**

Application

**EP 00990877 A 20001110**

Priority

- IN 0000110 W 20001110
- IN 1106MA1999 A 19991115

Abstract (en)

[origin: WO0135943A2] Patients receive intravenous fluids in the form of, fluid, media, nutrients minerals vitamins antibiotics and other life saving drugs in a number of clinical conditions. It is also reliable and effective means of providing them predictable effects with minimum of inconvenience. This may be the only means of treatment feasible on many occasions as a measure of resuscitative procedure to revive the patients from critically ill state to a state of survival and back to normal life. The presently available fluids are inadequate in all aspect except the water content of the need of the patient. They are hypotonic in effect even though they are isotonic when used in critical conditions. The author has been feeling, the needs of the patients under such circumstances by the presently infused fluids are hardly met. Thus putting the patient in a state of disadvantage to face the situation and to recover back to normal. With the development of science the desires and expectations of the patients keep on improving in terms of better results, at less cost, effort and loss of working time, in previously treatable cases. And revival and prolongation of life when earlier they were not possible. Much has been achieved in these directions in medical science. As part of the treatment even today the intravenous infusions consist mainly of water dextrose electrolytes. Subsequently the same route has been utilized for administration of antibiotics, proteins and lipid solutions along with many other soluble materials needed in particular instances.

[origin: WO0135943A2] Intravenous infusion formulations comprising dextrose, insulin, electrolytes and optionally heparin and vitamins.

IPC 1-7

**A61K 31/00**

IPC 8 full level

**A61K 9/08** (2006.01); **A61K 38/28** (2006.01); **A61K 9/00** (2006.01); **A61K 9/10** (2006.01); **A61K 31/00** (2006.01); **A61K 31/047** (2006.01); **A61K 31/07** (2006.01); **A61K 31/14** (2006.01); **A61K 31/164** (2006.01); **A61K 31/19** (2006.01); **A61K 31/198** (2006.01); **A61K 31/355** (2006.01); **A61K 31/375** (2006.01); **A61K 31/4415** (2006.01); **A61K 31/455** (2006.01); **A61K 31/465** (2006.01); **A61K 31/51** (2006.01); **A61K 31/525** (2006.01); **A61K 31/593** (2006.01); **A61K 31/70** (2006.01); **A61K 31/7004** (2006.01); **A61K 31/714** (2006.01); **A61K 31/727** (2006.01); **A61K 33/04** (2006.01); **A61K 33/06** (2006.01); **A61K 33/14** (2006.01); **A61K 33/42** (2006.01); **A61K 38/05** (2006.01); **A61K 45/06** (2006.01); **A61K 47/02** (2006.01); **A61K 47/26** (2006.01); **A61P 1/16** (2006.01); **A61P 3/02** (2006.01); **A61P 3/10** (2006.01); **A61P 7/02** (2006.01); **A61P 9/10** (2006.01); **A61P 17/02** (2006.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01); **A61P 31/04** (2006.01); **A61P 35/00** (2006.01); **A61P 39/00** (2006.01); **A61P 39/02** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)

**A61K 9/0019** (2013.01); **A61K 31/07** (2013.01); **A61K 31/14** (2013.01); **A61K 31/164** (2013.01); **A61K 31/198** (2013.01); **A61K 31/355** (2013.01); **A61K 31/375** (2013.01); **A61K 31/4415** (2013.01); **A61K 31/455** (2013.01); **A61K 31/51** (2013.01); **A61K 31/525** (2013.01); **A61K 31/593** (2013.01); **A61K 31/7004** (2013.01); **A61K 31/714** (2013.01); **A61K 31/727** (2013.01); **A61K 33/04** (2013.01); **A61K 33/14** (2013.01); **A61K 33/42** (2013.01); **A61K 38/05** (2013.01); **A61K 38/28** (2013.01); **A61K 45/06** (2013.01); **A61K 47/02** (2013.01); **A61K 47/26** (2013.01); **A61P 1/16** (2017.12); **A61P 3/02** (2017.12); **A61P 3/10** (2017.12); **A61P 7/02** (2017.12); **A61P 9/10** (2017.12); **A61P 17/02** (2017.12); **A61P 25/00** (2017.12); **A61P 25/28** (2017.12); **A61P 31/04** (2017.12); **A61P 35/00** (2017.12); **A61P 39/00** (2017.12); **A61P 39/02** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 0135943A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

**WO 0135943 A2 20010525; WO 0135943 A3 20020321;** AU 3048901 A 20010530; AU 779798 B2 20050210; AU 779798 C 20051117; CN 1284522 C 20061115; CN 1390118 A 20030108; EP 1231907 A2 20020821; JP 2003514014 A 20030415; RU 2002116377 A 20040127; RU 2300367 C2 20070610; ZA 200204895 B 20030212

DOCDB simple family (application)

**IN 0000110 W 20001110;** AU 3048901 A 20001110; CN 00815701 A 20001110; EP 00990877 A 20001110; JP 2001537936 A 20001110; RU 2002116377 A 20001110; ZA 200204895 A 20020614